Sculpting nursing resilience: Transforming lives, nurturing ethics in chimeric antigen receptor T-cell therapy

Keywords

A4R / Immunotherapy / Nursing healthcare service

References

[1] Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14.

[2] Bijnsdorp FM, Onwuteaka-Philipsen BD, Boot CR, van der Beek AJ, Pasman HR. Caregiver's burden at the end of life of their loved one: insights from a longitudinal qualitative study among working family caregivers. BMC Palliat Care. 2022;21(1):1-22.

[3] Beaupierre A, Kahle N, Lundberg R, Patterson A. Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy. J Adv Pract Oncol. 2019;10(3):29. Suppl.

[4] Bell JA, Jeffries GA, Chen CI. Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy. Blood. 2023;142(15):1263-1270.

[5] Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB. Regulatory measures to improve the safety of CAR-T-cell treatment. Transfus Med Hemother. 2023;50(3):218-225.

[6] Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707-715.

[7] Utkarsh K, Srivastava N, Kumar S, et al. CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clin Transl Oncol. 2024:1-9.

[8] Zhang K, Chen H, Li F, Huang S, Chen F, Li Y. Bright future or blind alley? CAR-T cell therapy for solid tumors. Front Immunol. 2023;14:1045024.

[9] Baer B. CAR T-cell therapy: updates in nursing management. Clin J Oncol Nurs. 2021;25(3):255-258.

[10] Puckrin R, Jamani K, Jimenez-Zepeda VH. Long-term survivorship care after CAR-T cell therapy. Eur J Haematol. 2024;112(1):41-50.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.